Table 1.
Studies included in Systematic Review.
Study | Study Type | Patient population | Antipsychotic type | Sample Type | DNA methylation approach |
---|---|---|---|---|---|
Abdolmaleky et. al [16]a | obs | Set 1 (saliva): 30 SCZ;30 HC;15 PR Set 2 (brain): 35 SCZ/BD;35 HC |
NR | saliva and brain | gene-specific |
Abdolmaleky et al. [17] | obs | 35 SCZ; 35 BD; 35 HC | NR | brain | gene-specific |
Abdolmaleky et al. [18] | obs | 40 SCZ; 35 BD; 40 HC | NR | brain | gene-specific |
Abdolmaleky et al. [19] | obs | Set 1 (brain): 35 SCZ/BD;35 HC Set 2 (saliva): 30 SCZ;20 BD;30 HC;20 UPR |
NR | saliva and brain | gene-specific |
Bönsch et al. [20] | obs | 20 twin pairs discordant for SCZ; 8 pairs concordant for SCZ; 21 HC twin pairs; 21 psychiatric control twin pairs | AAP and TAP | blood | global and gene-specific |
Bromberg et al. [21] | obs | 28 SCZ; 26 HC | NR | blood | global |
Burghardt et al. [22]b | obs | 120 BD | AAP | bloodd | EWAS |
Burghardt et al. [23]c | obs | Discovery Set: 96 SCZ; Validated Set: 166 SCZ | AAP | bloodd | EWAS |
Burghardt et al.[24] | obs | 30 BD | AAP | skeletal muscle | gene-specific |
Burghardt et al. [25] | obs | 115 BD | AAP | blood | global |
Burghardt et al. [26] | obs | 133 SCZ | AAP and TAP | blood | global |
Cheng et al. [27] | obs and prosp | 60 SCZ; 30 HC | risperidone | blood | gene-specific |
D’Addario et al.[28] | obs | 24 MDD;24 BD I; 24 BD II; 25 SCZ; 34 HC | AAP and TAP | blood | gene-specific |
Ellingrod et al. [29] | prosp | 35 SCZ | AAP and TAP | blood | global |
Houtepen et al. [30] | obs | 172 BD | olanzapine and quetiapine | bloodd | EWAS and gene-specific |
Kinoshita et al. [31] | prosp | 21 SCZ | olanzapine | blood | EWAS |
Li et al. [32] | obs | 92 SCZ; 99 BD; 92 HC | AAP and TAP | blood | global |
Lott et al. [33] | obs | 85 SCZ | NR | blood | gene-specific |
Melas et al. [34] | obs | 177 SCZ; 171 HC | AAP and TAP | blood | global and gene-specific |
Mill et al. [35] | obs | 35 SZ; 35 BD; 35 HC | NR | brain | EWAS |
Miura et al. [36] | prosp | 34 SCZ | risperidone | blood | gene-specific |
Moons et al. [37] | obs | 438 SCZ | AAP and TAP | blood | gene-specific |
Nour El Huda et al. [38] | obs | 138 SCZ; 132 HC | AAP and TAP | blood | gene-specific |
Rukova et al. [39] | prosp | 20 SCZ; 220 HC | NR | blood | EWAS |
Shi et al. [40] | prosp | 288 SCZ | risperidone | blood | gene-specific |
Swathy et al. [41] | obs | 184 SCZ; 330 HC | NR | blood | global |
Tang et al. [42] | prosp | 82 SCZ | AAP and TAP | blood | gene-specific |
Venugopal et al. [43] | prosp | 47 SCZ; 47 HC | AAP | blood | gene-specific |
Zong et al. [44] | obs | 279 SCZ; 265 HC | AAP and TAP | blood | gene-specific |
Details of 29 studies included in the systematic review including study design, type of antipsychotic within study, sample type for DNA methylation analysis, and overall DNA methylation strategy. Abbreviations: AAP = atypical antipsychotic; BD = bipolar disorder; EWAS = Epigenome-Wide Association Study; HC = healthy control; MDD = major depressive disorder; NR = not reported; obs = observational; PR = primary relative; pros =prospective; scz = schizophrenia; TAP = typical antipsychotic; UPR = unaffected primary relative
Abdolmakey et al. studies (references 16–19) did not state if patient overlap was present for included samples
Controlled for cell type composition